Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Oxaliplatin + FOLFIRI for Peritoneal Carcinomatosis
NCT02833753Phase 1Completed
- Sponsor
- University of Massachusetts
- Start
- Jul 2016
- Primary completion
- Feb 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), appendix cancer and peritoneal carcinomatosis (PC), sponsored by University of Massachusetts. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Jul 2016; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)appendix cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02833753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833753.